Overview

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

Status:
Terminated
Trial end date:
2017-12-29
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a single center double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure.
Phase:
Phase 3
Details
Lead Sponsor:
Aultman Health Foundation
Muhammad Chaudhry, MD
Treatments:
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Metolazone
Mineralocorticoid Receptor Antagonists